世界中の市場調査レポートを販売!当社に無いレポートもお探しします。

レポートナンバー 0000032651

世界の子癇前症診断市場に対するCOVID-19の影響-市場規模、シェア、動向分析2014-2019と2030年までの予測

Fatpos Global

COVID-19 Impact on Global Preeclampsia Diagnostics Market-Analysis of Market Size, Share and Trends for 2014 - 2019 and Forecasts to 2030

発刊日 2022/05

言語英語

体裁Word-PDF/291ページ

ライセンス/価格291ページ

0000032651

Single
Global Site License

※ご請求は、お申込日のTTSレートで円換算し、消費税を加えた金額になります。
※本レポートは、英文です。Word-PDF(電子媒体)での納品となります。
※本レポートは取り寄せとなりますので、申し込みからお届けまで、多少時間が掛かる場合がございます。

無料サンプル

  • サンプルはお問い合わせください。

レポート概要

世界の子癇前症診断市場に対するCOVID-19の影響:検査の種類別(血液検査および尿分析)。製品の種類別(機器および消耗品);エンドユーザー(病院、専門クリニック、診断センターなど)および地域別- 2014年から2019年の市場規模、シェア、動向の分析、および2030年までの予測

レポート詳細

目次

Contents

1. Executive Summary

2. Preeclampsia Diagnostics Market
2.1. Product Overview
2.2. Market Definition
2.3. Segmentation
2.4. Assumptions and Acronyms

3. Research Methodology
3.1. Research Objectives
3.2. Primary Research
3.3. Secondary Research
3.4. Forecast Model
3.5. Market Size Estimation

4. Average Pricing Analysis

5. Market Dynamics
5.1. Growth Drivers
5.2. Restraints
5.3. Opportunity
5.4. Trends

6. Correlation & Regression Analysis
6.1. Correlation Matrix
6.2. Regression Matrix

7. Recent Development, Policies & Regulatory Landscape

8. Risk Analysis
8.1. Demand Risk Analysis
8.2. Supply Risk Analysis

9. Preeclampsia Diagnostics Market Analysis
9.1. Porters Five Forces
9.1.1. Threat of New Entrants
9.1.2. Bargaining Power of Suppliers
9.1.3. Threat of Substitutes
9.1.4. Rivalry
9.2. PEST Analysis
9.2.1. Political
9.2.2. Economic
9.2.3. Social
9.2.4. Technological

10. Preeclampsia Diagnostics Market
10.1. Market Size & forecast, 2019A-2030F
10.1.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10.1.2. By Volume (Million Units) 2019-2030F; Y-o-Y Growth (%) 2020-2030F

11. Preeclampsia Diagnostics Market: Market Segmentation
11.1. By Regions
11.1.1. North America:(U.S. and Canada)
11.1.1.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
11.1.2. Latin America: (Brazil, Mexico, Argentina, Rest of Latin America)
11.1.2.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
11.1.3. Europe: (Germany, UK, France, Italy, Spain, BENELUX, NORDIC, Hungary, Poland, Turkey, Russia, Rest of Europe)
11.1.3.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
11.1.4. Asia-Pacific: (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia Pacific)
11.1.4.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
11.1.5. Middle East and Africa: (Israel, GCC, North Africa, South Africa, Rest of Middle East and Africa)
11.1.5.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F

12. Preeclampsia Diagnostics Market: Market Segmentation
12.1. By test type: Market Share (2020-2030F)
12.1.1. Blood test, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.1.2. Urine analysis, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.2. By product type: Market Share (2020-2030F)
12.2.1. instruments, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.2.2. consumables, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.3. By end-user: Market Share (2020-2030F)
12.3.1. hospitals, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.3.2. specialty clinics, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.3.3. diagnostic centers, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.3.4. others, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F

13. Company Profile
13.1. Bayer AG
13.1.1. Company Overview
13.1.2. Company Total Revenue (Financials)
13.1.3. Market Potential
13.1.4. Global Presence
13.1.5. Key Performance Indicators
13.1.6. SWOT Analysis
13.1.7. Product Launch
13.2. Roche
13.3. PerkinElmer
13.4. DRG INSTRUMENTS GMBH
13.5. Thermo Fisher Scientific
13.6. Diabetomics, Inc.
13.7. Metabolomic Diagnostics Ltd.
13.8. Sera Prognostics
13.9. Siemens Healthineers
13.10. Other prominent players
Consultant Recommendation
**The above-given segmentations and companies could be subjected to further modification based on in-depth feasibility studies conducted for the final deliverable

この商品のレポートナンバー

0000032651

TOP